Home

Concurrent Analytical is the inventor of Ramanprobes.

Ramanprobes is a revolutionary new method in point-of-care diagnostics that enables the possibility to detect and identify multiple cancer biomarkers concurrently in seconds, at the sensitivity and specificity necessary for early cancer diagnosis. 

Only a drop of blood is necessary for the analysis.

Ramanprobes has been used successfully in the early detection of pancreatic cancer and could be used for most cancers where biomarkers have been identified. 

It is our vision and goal that when combined with the ongoing industry effort using proteomics to identify cancer biomarkers, Ramanprobes will be the diagnostic method of choice to profile those biomarkers.  Ramanprobes has the ability to provide the detection and identification of cancer through biomarkers at an earlier stage then by other methods - thereby affording the best chance of recovery.

When combined with our patent pending gold nanorods currently being evaluated for in-vivo solid tumor cancer therapy (see nanopartz.com), Concurrent Analytical provides a one-two punch in the fight against cancer.

Concurrent Analytical maintains two commercial divisions; Nanopartz and Directed Bioflux.  The mission of Nanopartz is to commercialize many of the technologies developed through Concurrent Analytical that have wide ranging applications. These technologies are specifically focused on newly patent pending, patented, or proprietary technologies in nanomaterials, nanoparticles, and nanostructures. So for instance, whereas gold nanorods were originally developed for use in enhancing the Extrinsic Raman Label technology, they also have a tremendous value in photothermal cancer therapy as well. Nanopartz horizontally markets these products to a wide range of applications.

Directed Bioflux (see dbflux.com, coming soon) is another entity whose purpose is to commercialize many of the technologies developed through Concurrent Analytical. However, Directed Bioflux is specifically focused on  patented, patent pending  or proprietary technologies that reduce incubation times in heterogeneous immunoassays. These technologies will reduce total assay times in ELISA, fluorescence, as well as any other diagnostic that requires a reduction in mass transport times.

Select an icon below to visit our divisions.